TRANSTHYRETIN AMYLOIDOSIS
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New scan aims to spot rare heart disease earlier
Diagnosis Recruiting nowThis study is testing a new imaging method using a special tracer called I-124 evuzumitide to better diagnose cardiac amyloidosis, a condition where abnormal proteins build up in the heart and other organs. About 150 adults with known or suspected amyloidosis will receive a PET/M…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Oregon Health and Science University • Aim: Diagnosis
Last updated May 22, 2026 13:51 UTC
-
Breakthrough trial aims to prevent inherited amyloidosis in young adults
Prevention Recruiting nowThis study tests an experimental drug called acoramidis in 587 adults aged 18–75 who carry a faulty gene that causes transthyretin amyloidosis (ATTR) but have no symptoms yet. The drug aims to stabilize a key protein and prevent or delay the buildup of harmful plaques in the hear…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Prevention
Last updated May 26, 2026 04:32 UTC
-
Major study tracks Real-World impact of rare heart and nerve disease
Knowledge-focused Recruiting nowThis study will follow about 1,850 people with ATTR amyloidosis, a rare disease that affects the heart and nerves. Researchers will collect information on symptoms, treatments, and outcomes over time to better understand the disease and how current treatments work in everyday pra…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 26, 2026 04:35 UTC
-
New study tracks eplontersen safety in pregnancy and breastfeeding
Knowledge-focused Recruiting nowThis study watches for health problems in pregnant or breastfeeding women who have taken eplontersen for transthyretin amyloidosis, and in their babies up to one year old. It does not give any treatment—it only collects information from real-world cases. The goal is to better und…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC